AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32207636 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office ICM insertion
Number of subjects: 482
Study 32207636 — intervention group
Group type: COMPARATOR
Intervention: In-hospital ICM insertion
Number of subjects: 482
Study 34264701 — intervention group
Group type: EXPERIMENTAL
Intervention: TranS‐C + UC (n = 61; 8 individual weekly sessions)
Number of subjects: 121
Study 35484442 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 35484442 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33066746 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNACT Model of Care (MoC) for 3 months
Number of subjects: 100
Study 33066746 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 33066746 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNACT MoC
Number of subjects: 100
Study 32419414 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 32419414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 0
Study 34974435 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment reinforcing reductions in theta activity
Number of subjects: 20
Study 34974435 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving random rewards
Number of subjects: 20
Study 32343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant
Number of subjects: 0
Study 32343348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate Extended Release
Number of subjects: 0
Study 35737076 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Therapy (RT)
Number of subjects: 37
Study 35737076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 37
Study 35737076 — intervention group
Group type: COMPARATOR
Intervention: Active Control Treatment (AC)
Number of subjects: 37
Study 34190086 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Fit group (high-intensity interval exercises, 6-month home-based digitally supported program)
Number of subjects: 40
Study 34190086 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Fit group
Number of subjects: 40
Study 32949103 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Access to ART for All (EAAA)
Number of subjects: 3405
Study 32949103 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 3405
Study 36543445 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for focal CAD
Number of subjects: 103
Study 36543445 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) for diffuse CAD
Number of subjects: 103
Study 32250021 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat 2-mg tablet
Number of subjects: 64
Study 32250021 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat 4-mg tablet
Number of subjects: 64
Study 36342737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide system during MFU-V treatment
Number of subjects: 10
Study 32058976 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-featured study app
Number of subjects: 328
Study 32058976 — intervention group
Group type: COMPARATOR
Intervention: Control group with fewer app features
Number of subjects: 328
Study 33413982 — intervention group
Group type: EXPERIMENTAL
Intervention: SOVTE-Therapeutic Program (SOVTE-TP)
Number of subjects: 18
Study 33413982 — intervention group
Group type: COMPARATOR
Intervention: Vocal Function Exercises (VFE)
Number of subjects: 18
Study 33135429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4–6 mg/day)
Number of subjects: 269
Study 33135429 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5–7.5 mg/day)
Number of subjects: 269
Study 33135429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 269
Study 33135429 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 269
Study 32943093 — intervention group
Group type: EXPERIMENTAL
Intervention: Salford Lung Studies (SLS)
Number of subjects: 10
Study 35121270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for antenatal depression
Number of subjects: 444
Study 35121270 — intervention group
Group type: COMPARATOR
Intervention: Control group (not intervened)
Number of subjects: 444
Study 33298407 — intervention group
Group type: EXPERIMENTAL
Intervention: First facemask application
Number of subjects: 128
Study 33298407 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent facemask applications
Number of subjects: 128
Study 33298407 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask applications associated with apnoea
Number of subjects: 128
Study 33006068 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised web‐based testing
Number of subjects: 17473
Study 33006068 — intervention group
Group type: COMPARATOR
Intervention: Supervised paper‐based testing
Number of subjects: 17473
Study 33006068 — intervention group
Group type: COMPARATOR
Intervention: Supervised computerized testing
Number of subjects: 17473
Study 32145830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 663
Study 32145830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study 33550450 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 153
Study 34716989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonviolent communication (NVC) training for 2.5 days
Number of subjects: 312
Study 34716989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NVC training)
Number of subjects: 312
Study 35688587 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol titrated by anaesthesia practitioners able to interpret EEG
Number of subjects: 200
Study 35688587 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring (BIS)
Number of subjects: 200
Study 33760371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 11
Study 33760371 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 11
Study 33161581 — intervention group
Group type: EXPERIMENTAL
Intervention: Screencast training videos
Number of subjects: 53
Study 33161581 — intervention group
Group type: COMPARATOR
Intervention: Traditional training videos on CBCT and implant planning
Number of subjects: 53
Study 35500028 — intervention group
Group type: COMPARATOR
Intervention: Prenatal multiple micronutrient supplementation (MMS)
Number of subjects: 53
Study 35500028 — intervention group
Group type: COMPARATOR
Intervention: Prenatal lipid‐based nutrient supplementation (LNS)
Number of subjects: 53
Study 35500028 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine iron‐folic acid (IFA) supplementation
Number of subjects: 53
Study 32301640 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Sheet (TS)
Number of subjects: 72
Study 32301640 — intervention group
Group type: COMPARATOR
Intervention: S45
Number of subjects: 72
Study 32301640 — intervention group
Group type: COMPARATOR
Intervention: S90
Number of subjects: 72
Study 35487299 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg per day for 8 weeks
Number of subjects: 21
Study 35487299 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 21
Study 34158099 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable + Symptom Data Algo (Ava bracelet data + Daily Symptom Diary data)
Number of subjects: 20000
Study 34158099 — intervention group
Group type: COMPARATOR
Intervention: Symptom Only Algo (Daily Symptom Diary data alone)
Number of subjects: 20000
Study 70655980 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 3-8 ng/mL
Number of subjects: 0
Study 70655980 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 6-12 ng/mL
Number of subjects: 0
Study 70655980 — intervention group
Group type: COMPARATOR
Intervention: Control group (Mycophenolate sodium 1.44 g/day with standard dose CsA)
Number of subjects: 0
Study 70655980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EVR groups
Number of subjects: 0
Study 70655980 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 70655980 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 0
Study 33754246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity physical activity (300 min/week, 40-59% HRR)
Number of subjects: 45
Study 33754246 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity (150 min/week, 60-80% HRR)
Number of subjects: 45
Study 33754246 — intervention group
Group type: COMPARATOR
Intervention: No intervention/control
Number of subjects: 45
Study 34074812 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 32
Study 34074812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33810609 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise regimen (12 weeks)
Number of subjects: 70
Study 33810609 — intervention group
Group type: COMPARATOR
Intervention: Dietary restriction (control group)
Number of subjects: 70
Study 33275070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD4 count (<350 cells/μL)
Number of subjects: 595
Study 33275070 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic use in last 4 weeks
Number of subjects: 595
Study 33275070 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count ≥350 cells/μL
Number of subjects: 595
Study 33275070 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of ESBL‐PE carriage
Number of subjects: 595
Study 32282934 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard information and a reminder letter
Number of subjects: 184
Study 32282934 — intervention group
Group type: COMPARATOR
Intervention: Standard information according to clinical routine
Number of subjects: 184
Study 32631427 — intervention group
Group type: EXPERIMENTAL
Intervention: Eurythmy therapy (ERYT)
Number of subjects: 196
Study 32631427 — intervention group
Group type: COMPARATOR
Intervention: CoordiFit (control)
Number of subjects: 196
Study 35136919 — intervention group
Group type: EXPERIMENTAL
Intervention: Social threat condition (participants rejected by confederates)
Number of subjects: 83
Study 35136919 — intervention group
Group type: COMPARATOR
Intervention: Social acceptance condition (participants supported by confederates)
Number of subjects: 83
Study 33933722 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 (EPA + DHA)
Number of subjects: 39
Study 33933722 — intervention group
Group type: COMPARATOR
Intervention: n-6 (LA)
Number of subjects: 39
Study 34266520 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg amputation method
Number of subjects: 24
Study 34266520 — intervention group
Group type: COMPARATOR
Intervention: Cardiocentesis
Number of subjects: 24
Study 32622346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP therapy (<120/80 mm Hg)
Number of subjects: 123
Study 32622346 — intervention group
Group type: COMPARATOR
Intervention: Standard BP therapy (<140/90 mm Hg)
Number of subjects: 123
Study 35226703 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Garment (CG)
Number of subjects: 12
Study 35226703 — intervention group
Group type: COMPARATOR
Intervention: Sports Pants (SP)
Number of subjects: 12
Study 35226703 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Garment (CG) and Sports Pants (SP)
Number of subjects: 12
Study 32715152 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral thoracic sympathectomy in dominant side
Number of subjects: 200
Study 32715152 — intervention group
Group type: COMPARATOR
Intervention: One-stage bilateral thoracic sympathectomy
Number of subjects: 200
Study 34981703 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 75% of total carbohydrates as whole grains
Number of subjects: 0
Study 34981703 — intervention group
Group type: COMPARATOR
Intervention: Diet with 75% of total carbohydrates as refined grains
Number of subjects: 0
Study 32023922 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelica Gigas Nakai Extract (AGNE) 1 g/day (200 mg/dose) for 12 weeks
Number of subjects: 100
Study 32023922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34688549 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (PT)
Number of subjects: 0
Study 34688549 — intervention group
Group type: COMPARATOR
Intervention: Photon radiation therapy (IMRT)
Number of subjects: 0
Study 33302644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan-zhen Jie-ci (FZJC) acupuncture therapy
Number of subjects: 76
Study 33302644 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture treatment
Number of subjects: 76
Study 32107266 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIOMET treatment (low-dose combination of spironolactone, pioglitazone, and metformin)
Number of subjects: 51
Study 32107266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 51
Study 32107266 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 51
Study 32107266 — intervention group
Group type: COMPARATOR
Intervention: Oral contraception-based treatment
Number of subjects: 51
Study 36114656 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioral therapy (iCBT)
Number of subjects: 5017
Study 36114656 — intervention group
Group type: COMPARATOR
Intervention: general-information (control)
Number of subjects: 5017
Study 33091857 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis oral spray (2-4 sprays three times/day for five days, total polyphenol content 15 mg/ml)
Number of subjects: 122
Study 33091857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 33091857 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis oral spray
Number of subjects: 122
Study 32442153 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAN intervention (digital and dietetic-delivered program)
Number of subjects: 22
Study 32442153 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face dietitian consultations, weight tracker, website information delivery, SMS goal prompting
Number of subjects: 22
Study 32442153 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAN intervention
Number of subjects: 22
Study 32442153 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of intervention components
Number of subjects: 22
Study 34750839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 12.0 μg·kg‐1 ·min‐1
Number of subjects: 120
Study 34750839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 6.0 μg·kg‐1 ·min‐1
Number of subjects: 120
Study 34750839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 9.0 μg·kg‐1 ·min‐1
Number of subjects: 120
Study 34750839 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 6.0 μg·kg‐1 ·min‐1 and 9.0 μg·kg‐1 ·min‐1
Number of subjects: 120
Study 34270094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer vaccine
Number of subjects: 1736
Study 34270094 — intervention group
Group type: EXPERIMENTAL
Intervention: AstraZeneca vaccine
Number of subjects: 1736
Study 34270094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinopharm vaccine
Number of subjects: 1736
Study 34270094 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 1736
Study 34270094 — intervention group
Group type: EXPERIMENTAL
Intervention: Unusual side effects
Number of subjects: 1736
Study 32648393 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-snake moxibustion
Number of subjects: 120
Study 32648393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion at ashi point
Number of subjects: 120
Study 32648393 — intervention group
Group type: COMPARATOR
Intervention: Waiting for treatment group
Number of subjects: 120
Study 35866597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve strain Bif195
Number of subjects: 126
Study 35866597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 33926653 — intervention group
Group type: EXPERIMENTAL
Intervention: High Sodium (HS) diet (300 mEq sodium/day)
Number of subjects: 14
Study 33926653 — intervention group
Group type: COMPARATOR
Intervention: Low Sodium (LS) diet (10 mEq sodium/day)
Number of subjects: 14
Study 32410601 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 405
Study 35451469 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 g of magnesium daily (4 tablets of 0.4 g each twice daily) for 72 hours preoperatively and 1.6 g of magnesium on the day of surgery
Number of subjects: 200
Study 35451469 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 200
Study 32572800 — intervention group
Group type: EXPERIMENTAL
Intervention: BUPA + OXY
Number of subjects: 43
Study 32572800 — intervention group
Group type: EXPERIMENTAL
Intervention: BUPA + ITMs
Number of subjects: 43
Study 32572800 — intervention group
Group type: EXPERIMENTAL
Intervention: BUPA + OXY + ITMs
Number of subjects: 43
Study 32651030 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative approach consisting of 12 sessions of 90 min each, including psychoeducation, mindfulness training, and cognitive and functional enhancement strategies.
Number of subjects: 132
Study 32651030 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 132
Study 36429384 — intervention group
Group type: EXPERIMENTAL
Intervention: MIND Diet
Number of subjects: 72
Study 36429384 — intervention group
Group type: EXPERIMENTAL
Intervention: MIND Diet plus Forest Bathing (FB)
Number of subjects: 72
Study 36429384 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 72
Study 34955774 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (tDCSa)
Number of subjects: 26
Study 34955774 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (tDCSs)
Number of subjects: 26
Study 32636239 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB radiomic biomarker (TMBRB) developed using 3D-densenet and 1020 deep learning features.
Number of subjects: 327
Study 32636239 — intervention group
Group type: COMPARATOR
Intervention: TMBRB compared to histological subtype.
Number of subjects: 327
Study 32636239 — intervention group
Group type: COMPARATOR
Intervention: TMBRB compared to Radiomic model.
Number of subjects: 327
Study 32636239 — intervention group
Group type: EXPERIMENTAL
Intervention: TMBRB predicting immunotherapy efficacy.
Number of subjects: 327
Study 32636239 — intervention group
Group type: EXPERIMENTAL
Intervention: TMBRB combined with Eastern Cooperative Oncology Group performance status.
Number of subjects: 327
Study 36169994 — intervention group
Group type: EXPERIMENTAL
Intervention: Calm mindfulness app
Number of subjects: 1029
Study 33481482 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated sunlight (1.3× standard erythemal dose, three times per week for 4 weeks and then once per week for 8 weeks)
Number of subjects: 250
Study 33481482 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (1000 IU·d‐1 for 4 weeks and then 400 IU·d‐1 for 8 weeks)
Number of subjects: 250
Study 33481482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 32924893 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance goals
Number of subjects: 121
Study 32924893 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance coping condition
Number of subjects: 121
Study 32924893 — intervention group
Group type: COMPARATOR
Intervention: Distraction coping condition
Number of subjects: 121
Study 33370477 — intervention group
Group type: EXPERIMENTAL
Intervention: third-party bone marrow-derived MSC infusion
Number of subjects: 20
Study 33370477 — intervention group
Group type: COMPARATOR
Intervention: standard of care alone
Number of subjects: 20
Study 36445909 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound at 0.4 W/cm2 and 100% duty cycle
Number of subjects: 28
Study 36445909 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound at varying intensities and duty cycles
Number of subjects: 28
Study 36445909 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound at varying intensities
Number of subjects: 28
Study 32534731 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV-guided fluid management strategy (fluids given whenever PPV was higher than 12%)
Number of subjects: 40
Study 32534731 — intervention group
Group type: COMPARATOR
Intervention: Liberal fluid strategy (10 mL.kg‐1.h‐1 following institutional standard care protocol)
Number of subjects: 40
Study 35001863 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional endoscope
Number of subjects: 70
Study 35001863 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional endoscope
Number of subjects: 70
Study 33905827 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavandula angustifolia essential oil inhalation for 29 days
Number of subjects: 35
Study 33905827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil) inhalation for 29 days
Number of subjects: 35
Study 36397215 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at back-shu points (Ganshu, Xinshu, Pishu, Feishu, Shenshu) with continuous wave, 2 Hz frequency, 20 min each time, once every other day, for 3 courses (2 weeks each).
Number of subjects: 72
Study 36397215 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture at non-acupoints with shallow needling, no current, same treatment duration as EA group.
Number of subjects: 72
Study 36397215 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at back-shu points (Ganshu, Xinshu, Pishu, Feishu, Shenshu).
Number of subjects: 72
Study 32174362 — intervention group
Group type: EXPERIMENTAL
Intervention: N-back task (cognitive load)
Number of subjects: 0
Study 32174362 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate Reference Task (SuRT) (visual load)
Number of subjects: 0
Study 32174362 — intervention group
Group type: COMPARATOR
Intervention: No non-driving related task (control condition)
Number of subjects: 0
Study 32174362 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy non-driving related task (cognitive load)
Number of subjects: 0
Study 32174362 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult non-driving related task (cognitive load)
Number of subjects: 0